5/10
08:39 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
High
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
4/23
08:09 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/18
02:52 pm
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
3/14
07:24 am
btai
Rating for BTAI
Low
Report
Rating for BTAI
2/21
08:00 am
btai
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
Medium
Report
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) had its "neutral" rating re-affirmed by analysts at UBS Group AG. They now have a $4.00 price target on the stock, down previously from $9.00.
2/21
07:38 am
btai
Rating for BTAI
Medium
Report
Rating for BTAI